Lawrence H. Boise, Ph.D., associate professor of Microbiology and Immunology at the University of Miami Leonard M. Miller School of Medicine, and his team found that some multiple myeloma cell lines responded to a compound called ZIO-101 in the lab. Dr. Boise, Kelvin P. Lee, M.D., professor of Microbiology and Immunology, and their colleagues at the UM Miller School of Medicine have extensive experience working with arsenic trioxide (ATO), which was FDA-approved in September 2000 for the treatment of acute promyelocytic leukemia.
"We've had a longstanding interest in studying the mechanism, action and activity of arsenicals in multiple myeloma," said Boise
studies have shown that ZIO-101 has much less toxicity and so if you can have similar anti-tumor activity with less toxicity you can give more of the drug, improving your results," said Boise
, Lee and their colleagues tested ZIO-101 on four different multiple myeloma cell lines, finding mixed results.
"So the ZIO-101 has a different mechanism or metabolism than arsenic trioxide," said Boise
."What this means is patients who don't respond well to arsenic trioxide may respond well to ZIO-101, and vice versa."Claire Croutch, Ph.D., a postdoctoral fellow in the laboratory of Dr. Boise, will present the work in a research poster from 1 to 5 p.m. on Tuesday, April 4, at the AACR meeting in Washington, D.C.